江蘇荃信生物醫藥股份有限公司（02509）于2026年1月12日发布翌日披露报表，公告显示公司于当日回购79,600股H股。该回购占公司本次公告前已发行股本（不包括库藏股）约0.0353%。回购完成后，公司已发行股本（不包括库藏股）为225,416,200股，库藏股增至1,655,400股。
本次回购价格区间介乎每股HKD 21.68至HKD 22.08，合计付出约HKD 1,750,220.92。公司表示，此次回购根据2025年6月20日通过的购回授权进行，授权总数为22,207,160股。截至目前，基于该授权已累计回购1,655,400股，占授权通过当日已发行股本（不包括库藏股）的0.7454%。
公告同时确认，本次回购遵守了香港联交所主板上市规则的相关规定，且与公司先前提交的函件资料不存在重大差异。该公告由董事会秘書和聯席公司秘書胡衍保签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.